Please enable JS

Investors & Media


CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Our lead program, CTX001, aims to treat Sickle cell disease and ß-thalassemia using an ex vivo approach. We are also pursuing oncology indications with our allogeneic CAR-T platform and liver, lung, and neuromuscular indications using in vivo approaches. In addition, we have established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases with high unmet need. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. We are headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and select business operations in London, United Kingdom.

Corporate Presentation

Preview of Module presentationsArchiveAudioColumn01.3
CRISPR Therapeutics Corporate Presentation

Recent News

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results
CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences
CRISPR Therapeutics Announces Transition of Bill Lundberg, MD

View More

Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet